{"url_path":"/sec/ions/8-k/2026-06-08/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-08","source_url":"https://www.sec.gov/Archives/edgar/data/874015/0001140361-26-024407-index.html","accession_number":"0001140361-26-024407","cik":"0000874015","ticker":"IONS","issuer_name":"IONIS PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/874015/0001140361-26-024407-index.html","primary_entity_key":"0000874015","primary_entity_name":"IONIS PHARMACEUTICALS INC"},"word_count":121,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn June 8, 2026, the Company issued a press release announcing that Dr. Hantson was appointed to the Company’s Board on June 4, 2026. A copy of the press release is\nfurnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Item 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as\namended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as\namended, or the Exchange Act, regardless of any general incorporation language in such filing."}